LifeMD Drops 7% as Traders Cash Out Before Earnings — But Did the Real Bad News Already Land?

Shares of LifeMD slid 7.2% to $3.62 on August 7, extending a sell-off that began after the telehealth company released Q2 2026 results two days ago. While the initial narrative centered on pre-earnings profit-taking after a run from $3.50 to $3.90 in four sessions, the picture is now clearer — and grimmer — following actual results that missed the Street's expectations and triggered a significant guidance cut.

Revenue Came In Light and the Full-Year Outlook Got Slashed

LifeMD reported Q2 revenue of $47.3 million, within its own guidance of $47–$50 million but down from $49.0 million a year earlier — and well below the Wall Street consensus of $49.15 million . More damaging, the company cut 2026 revenue guidance to $205.5–$212.5 million and adjusted EBITDA to -$6.0 million to breakeven, down sharply from prior guidance of $220–$230 million in revenue and $12–$17 million in EBITDA . That is a potential $25 million revenue haircut at the midpoint and a swing from expected profit to possible loss.

The Profitability Story Just Reversed

LifeMD had swung from a $21.4 million net loss in 2024 to $14.35 million in net income in 2025 , giving bulls a turnaround thesis. That narrative is now under stress. Adjusted EBITDA flipped to a $3.5 million loss versus a positive $3.9 million a year ago, though it improved roughly 21% sequentially . Management insists the second half will be better, but investors have heard that before — after Q1's beat, the stock still dropped 14.8% in a single day .

Subscriber Growth Is Real, but Not Paying Off Yet

Active subscribers grew 20% to roughly 356,000, including about 108,000 weight-management subscribers, and approximately 84% of revenue came from recurring subscriptions . Gross margin expanded about 280 basis points year-over-year to roughly 89% . The unit economics are improving, but total operating expenses ballooned to $49.1 million from $44.5 million , meaning heavy marketing spending is eating the margin gains.

Analysts Still See Upside — If You Believe the Targets

Eight analysts carry an average price target of $9.88, with a range of $8 to $15 . That implies roughly 170% upside from today's price. But with just $25.1 million in cash and no debt , the margin for execution error is thin. The coming quarters will determine whether LifeMD's weight-management bet is a growth engine or a cash furnace.